CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zynerba Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zynerba Pharmaceuticals Inc
80 W. Lancaster Avenue, Suite 300
Phone: (484) 581-7505p:484 581-7505 DEVON, PA  19333  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 10/11/2023.
This company ceased filing statements with the SEC on 10/19/2023.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer ArmandoAnido 65 10/1/2014 10/1/2014
President Terri B.Sebree 65 12/1/2014 10/1/2014
Chief Financial Officer, Vice President - Corporate Development James E.Fickenscher 59 1/1/2018 9/13/2016
7 additional Officers and Directors records available in full report.

Business Names
Business Name
ZYNE
Zynerba Pharmaceuticals Pty Ltd

General Information
Number of Employees: 25 (As of 3/22/2023)
Outstanding Shares: 53,939,431 (As of 8/9/2023)
Shareholders: 59
Stock Exchange: NASD
Federal Tax Id: 260389433
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, April 17, 2024